Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children

Br J Haematol. 2022 Jan;196(1):e6-e9. doi: 10.1111/bjh.17760. Epub 2021 Aug 3.
No abstract available

Keywords: ALL; CD19 targeting; CD19-negative precursors; flow cytometry; minimal residual disease.

Publication types

  • Letter

MeSH terms

  • Antibodies, Bispecific / administration & dosage
  • Antibodies, Bispecific / adverse effects
  • Antibodies, Bispecific / therapeutic use
  • Antigens, CD19 / metabolism*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Child
  • Child, Preschool
  • Clonal Evolution*
  • Humans
  • Molecular Targeted Therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / etiology*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Precursor Cells, B-Lymphoid / metabolism*
  • Precursor Cells, B-Lymphoid / pathology*
  • Treatment Outcome

Substances

  • Antibodies, Bispecific
  • Antigens, CD19
  • Antineoplastic Agents, Immunological
  • blinatumomab